A relevant study by Tosco and coworkers [141] showed that a combination treatment including the cystinosis drug cysteamine [142] and the flavonoid epigallocatechin gallate, two safe proteostasis regulators, reduced inflammatory cytokines by 30% in nasal cells and sputum of CF patients bearing at least one copy of Class II CFTR mutations, while concomitantly restoring CFTR function. The gene discussed is CFTR; the disease is cystinosis.